, Volume 40, Issue 11, pp 1278–1285

Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

  • R. G. Thompson
  • L. Pearson
  • O. G. Kolterman


The effects of 4 weeks’ administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial. Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 µg four times per day (breakfast, lunch, dinner, and evening snack), 30 µg three times per day (breakfast, lunch and dinner [BLD]), 30 µg three times per day (breakfast, dinner and evening snack [BDS]), and 60 µg twice per day (breakfast and dinner). After 4 weeks of pramlintide 30 µg four times per day administration, there was a statistically significant reduction in the mean 24 h plasma glucose concentration when compared to placebo (- 1.4 ± 0.5 vs 0.3 ± 0.5 µmol/1, p = 0.009). Serum fructosamine concentrations were reduced 62 ± 10 µmol/1 in the pramlintide 30 mg four times per day group, 43 ± 7 µmol/l in the pramlintide 30 µg three times per day (BLD) group, 47 ± 6 µmol/1 in the pramlintide 30 µg three times per day (BDS) group, 46 ± 7 µmol/1 in the pramlintide 60 µg twice per day group, and 29 ± 8 µmol/1 by placebo. The incidence of hypoglycaemia was not different in any pramlintide group compared to the placebo group. Nausea, the most frequent adverse event, subsided after the first week of treatment in the majority of patients. In conclusion, pramlintide improved blood glucose control over a 4-week period without increased hypoglycaemia and was well tolerated. Future studies using a longer period of pramlintide administration with assessment of HbA1c as the measurement of glycaemic control are warranted.


Pramlintide amylin serum fructosamine plasma glucose HbA1c IDDM 



area under the plasma concentration curve


maximum plasma concentration


minimum plasma concentration


not statistically significant


not applicable


breakfast, lunch and dinner


breakfast, dinner and evening snack


hemoglobin Alc


  1. 1.
    Cooper GSJ, Willis AC, Clark A et al. (1989) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628–8632CrossRefGoogle Scholar
  2. 2.
    Hartter E, Svoboda T, Ludvik B et al. (1991) Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia 34: 52–54PubMedCrossRefGoogle Scholar
  3. 3.
    Butler PC, Chou J, Carter B, Wang YN et al. (1990) Effects of meal ingestion on plasma amylin concentrations in NIDDM and nondiabetic humans. Diabetes 39: 752–756PubMedCrossRefGoogle Scholar
  4. 4.
    Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG (1992) Amylin concentrations and glucose control. Lancet 339: 1179–1180PubMedCrossRefGoogle Scholar
  5. 5.
    Gedulin BR, Rink TJ, Young AA (1997) Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 1–5CrossRefGoogle Scholar
  6. 6.
    Brown K, Menius A, Sandefer E, Edwards J, James M (1994) The effects of amylin on changes in plasma glucose and gastric emptying following an oral glucose load in conscious dogs. Diabetes 43 [Suppl 1]: 172 A (Abstract)Google Scholar
  7. 7.
    Young AA, Gedulin B, Vine W, Percy A, Rink TJ (1995) Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642–648PubMedCrossRefGoogle Scholar
  8. 8.
    Westermark P, Wernstedt C, Wilander E, Sletten K (1986) A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140: 826–831CrossRefGoogle Scholar
  9. 9.
    Kolterman OG, Gottlieb A, Moyses C, Colburn W (1995) Reduction of postprandial hyperglycaemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 18: 1179–1182PubMedCrossRefGoogle Scholar
  10. 10.
    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A (1996) Effect of 14 days subcutaneous administration of the human amylin analogue, pramlintide (AC 137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39: 492–499PubMedCrossRefGoogle Scholar
  11. 11.
    Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800–802CrossRefGoogle Scholar
  12. 12.
    Thompson RG, Peterson J, Gottlieb A, Mullane J (1997) Effects of pramlintide, a synthetic amylin analogue, on plasma glucose profiles in patients with insulin-dependent diabetes mellitus. Diabetes 46: 632–636PubMedCrossRefGoogle Scholar
  13. 13.
    Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE (1996) Amylin response following sustacal ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia 39 [Suppl 1]: A149Google Scholar
  14. 14.
    DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986CrossRefGoogle Scholar
  15. 15.
    The DCCT Research Group (1995) Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 18: 1415–1427CrossRefGoogle Scholar
  16. 16.
    MacDonald I, King P, Kong M-F, Stubbs T, Perkins A, Moyses, Tattersall R (1995) Infusion of the human amylin analogue, AC137, delays gastric emptying in men with IDDM. Diabetologia 38 [Suppl 1]: A32 (Abstract)CrossRefGoogle Scholar
  17. 17.
    Horowitz M, Fraser R (1994) Disordered gastric motor function in diabetes mellitus. Diabetologia 37: 543–551PubMedCrossRefGoogle Scholar
  18. 18.
    Nowak TV, Johnson CP, Kalbfleisch JH et al. (1995) Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 37: 23–29PubMedCrossRefGoogle Scholar
  19. 19.
    Kong MFSC, MacDonald IA, Tattersall RB (1996) Gastric emptying in diabetes. Diabet Med 13: 112–119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • R. G. Thompson
    • 1
  • L. Pearson
    • 1
  • O. G. Kolterman
    • 1
  1. 1.Amylin Pharmaceuticals Inc.San DiegoUSA

Personalised recommendations